AI Robotics in Medicine

Healthcare stocks fell Monday (NYSE Healthcare Index -1. 1%, XLV -0.

8%, IBB -1. 1%) even as Tempus AI moved to acquire Personalis for $1.

5B and Bristol-Myers expanded its NVIDIA collaboration—yet all three traded lower. Nuvation Bio defied the slide, rising over 8% on follow-up phase 2 data for safusidenib in a brain tumor (51.

9% ORR; 79. 1% PFS at 36 months).

The through-line: in a risk-off tape, investors are elevating the proof bar—AI partnerships look like spending and execution risk, while tangible clinical outcomes get rewarded; watch for AI to deliver faster trials, lower costs, or more approvals.

Tracking: Medicine Robotics · AI Medicine · AI Healthcare

Geography: United States, European Union, United Kingdom, China, Japan, South Korea, Israel, India, Singapore, United Arab Emirates

1. Healthcare Stocks Dropped as AI Deals Lagged, Nuvation Bio Rallied

Healthcare stocks slid Monday despite headline-grabbing AI and deal news. The NYSE Healthcare Index fell 1.

1%, the Health Care Select Sector SPDR Fund lost 0. 8%, and the iShares Biotechnology ETF dropped 1.

1%. Tempus AI announced a $1.

5 billion agreement to acquire Personalis, and Bristol-Myers Squibb said it widened its NVIDIA collaboration to build an “AI factory” for drug research — yet Tempus, Personalis, and Bristol-Myers all traded lower.

Nuvation Bio bucked the trend, climbing more than 8% after follow-up phase 2 data for safusidenib in a type of brain tumor showed a 51. 9% objective response rate and 79.

1% progression-free survival at 36 months. On risk-off days, markets “raise the proof bar”: longer-dated AI partnerships look like spending and execution risk, while clinical data is tangible.

Investors may wait for AI promises to translate into “faster trials, lower costs, or more approved drugs. ”

Key facts:

- NYSE Healthcare Index fell 1.1% Monday.

- Health Care Select Sector SPDR Fund (XLV) slipped 0.8%.

- iShares Biotechnology ETF (IBB) dropped 1.1%.

- Tempus AI agreed to buy Personalis for $1.5 billion.

- Tempus AI and Personalis traded lower after their tie-up.

Why it matters: Investors favored tangible clinical progress over long-dated AI narratives. On a down day, AI partnerships and M&A were treated as near-term spending and execution risk, while strong trial data moved capital to the perceived winners.

Near-term beneficiaries are companies posting clear efficacy signals, which can lift modeled approval odds and pipeline value. Firms touting AI collaborations need measurable outputs before markets re-rate them.

Watch for AI efforts that demonstrably produce “faster trials, lower costs, or more approved drugs.

” Until those show up, dispersion will likely persist: clinical winners can climb even as sector benchmarks fall, while AI headlines alone may not sustain share gains.

Finimize